Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RAD 001 Clear all
Completed Phase 2 Interventional Results available

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

NCT01797120
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, Everolimus, Placebo
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
25
States / cities
Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

NCT01058655
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Everolimus, Tivozanib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

NCT00680758
View directory record Official record
Conditions
Breast Cancer
Interventions
cisplatin, everolimus, paclitaxel
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Early Phase 1 Interventional

Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

NCT01880749
View directory record Official record
Conditions
Neurofibromatosis Type 2, Vestibular Schwannomas, Meningiomas
Interventions
RAD001
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 25, 2026, 6:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

NCT01188889
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
RAD001, Imatinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

NCT01827384
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm
Interventions
Adavosertib, Carboplatin, Everolimus, Temozolomide, Trametinib, Veliparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Aurora, Colorado • Atlanta, Georgia • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 4 Interventional Results available

Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus

NCT02338609
View directory record Official record
Conditions
Growth and Development
Interventions
Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Saint Paul, Minnesota • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

NCT01524783
View directory record Official record
Conditions
Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors
Interventions
Everolimus, Placebo, Best suportive care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 1Phase 2 Interventional

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

NCT00792766
View directory record Official record
Conditions
Tuberous Sclerosis, Angiolipoma
Interventions
everolimus (RAD001)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 1Phase 2 Interventional

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

NCT01510119
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Hydroxychloroquine, RAD001
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 25, 2026, 6:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

NCT01068249
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Letrozole, RAD001 (Everolimus)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
2
States / cities
Morristown, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 25, 2026, 6:23 PM EDT
Terminated Phase 2 Interventional Results available

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

NCT01239342
View directory record Official record
Conditions
Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Akt Inhibitor MK2206, Everolimus, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
8
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 25, 2026, 6:23 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of RAD001 Head and Neck Cancer

NCT01051791
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Everolimus 10mg daily
Drug
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 25, 2026, 6:23 PM EDT
Recruiting Phase 1 Interventional

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

NCT04485559
View directory record Official record
Conditions
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
Interventions
Everolimus, Trametinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Everolimus for Children With Recurrent or Progressive Ependymoma

NCT02155920
View directory record Official record
Conditions
Recurrent Childhood Ependymoma
Interventions
Everolimus
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Stanford, California • New York, New York • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 25, 2026, 6:23 PM EDT
Completed No phase listed Observational

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

NCT00636090
View directory record Official record
Conditions
Metastatic Hormone Refractory Prostate Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

NCT01150097
View directory record Official record
Conditions
Liver Transplant Recipient
Interventions
Tacrolimus (reduced tacrolimus), Everolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Everolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

NCT01031446
View directory record Official record
Conditions
Breast Cancer
Interventions
cisplatin, everolimus, paclitaxel, laboratory biomarker analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
4
States / cities
Chattanooga, Tennessee • Jackson, Tennessee • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

NCT00323739
View directory record Official record
Conditions
Kidney Cancer
Interventions
bevacizumab, RAD001
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Fort Myers, Florida • Gainesville, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

NCT00423865
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 25, 2026, 6:23 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

NCT00655252
View directory record Official record
Conditions
Metastatic Renal Cell Cancer
Interventions
Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
U.S. locations
15
States / cities
Springdale, Arkansas • Aurora, Colorado • Ocoee, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma

NCT01854606
View directory record Official record
Conditions
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Interventions
AEB071, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
St Louis, Missouri • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

NCT01182168
View directory record Official record
Conditions
Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
Interventions
gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 25, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

NCT02106507
View directory record Official record
Conditions
Prostate Cancer
Interventions
apalutamide, Everolimus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 25, 2026, 6:23 PM EDT